FDA Approves First CRISPR Therapy for Sickle Cell

On December 8, 2023, the U.S. Food and Drug Administration (FDA) made a decision that will likely be remembered as a turning point in medical history. The agency approved Casgevy (exagamglogene autotemcel), the first-ever treatment to utilize CRISPR/Cas9 gene-editing technology. This approval provides a “functional cure” for patients 12 years and older suffering from sickle cell disease, offering hope to approximately 100,000 Americans affected by this debilitating genetic disorder.

Understanding the Casgevy Breakthrough

Developed through a partnership between Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy represents a leap forward in precision medicine. While gene therapy has existed for some time, this is the first approved application of CRISPR, the “molecular scissors” technology that won its inventors the Nobel Prize in Chemistry in 2020.

Sickle cell disease causes the body to produce flawed hemoglobin, a protein in red blood cells that carries oxygen. These defective cells become rigid and crescent-shaped, causing them to clump together and block blood flow. This leads to excruciating pain episodes known as vaso-occlusive crises (VOCs), organ damage, and reduced life expectancy.

How the Treatment Works

Casgevy does not try to fix the mutated gene directly. Instead, it uses a clever workaround involving fetal hemoglobin.

  1. Collection: Doctors collect the patient’s own hematopoietic (blood) stem cells.
  2. Editing: In a specialized laboratory, the CRISPR/Cas9 technology acts on these cells. It cuts the DNA at the BCL11A gene. This gene is essentially a “brake” that stops the production of fetal hemoglobin after birth.
  3. Reactivation: By disabling the brake, the stem cells are programmed to resume producing high levels of fetal hemoglobin. This type of hemoglobin does not sickle and can effectively transport oxygen.
  4. Infusion: The edited cells are infused back into the patient. Once they engraft in the bone marrow, they produce healthy red blood cells that prevent the sickling process.

Clinical Trial Success Rates

The FDA approval was based on compelling data from clinical trials. The results were not just statistically significant; they were transformative for the patients involved.

In the primary efficacy analysis:

  • Freedom from Pain: 29 out of 30 evaluable patients (96.7%) remained free of severe vaso-occlusive crises for at least 12 consecutive months after treatment.
  • Hospitalization Reduction: 100% of the 30 patients avoided hospitalizations related to severe pain crises during that same period.

Before the trial, these patients experienced multiple severe pain episodes annually. After the one-time treatment, nearly all of them were essentially symptom-free regarding pain crises.

A Second Approval: Bluebird Bio’s Lyfgenia

On the same day it approved Casgevy, the FDA also approved a second gene therapy for sickle cell disease called Lyfgenia (lovotibeglogene autotemcel), developed by Bluebird Bio.

While both treat the same condition, they use different technologies:

  • Casgevy: Uses CRISPR gene editing to modify the BCL11A gene.
  • Lyfgenia: Uses a lentiviral vector (a delivery shell derived from a virus) to insert a modified gene that produces a form of adult hemoglobin designed to resist sickling.

Lyfgenia is priced higher than Casgevy and comes with a Boxed Warning on its label. The FDA requires this warning because a small number of patients in clinical trials developed hematologic malignancy (blood cancer), specifically acute myeloid leukemia, after treatment. Casgevy currently does not carry this specific Boxed Warning, though long-term monitoring is required for both therapies.

The Cost and Complexity of Treatment

While the science is groundbreaking, the logistics and economics present significant hurdles. This is not a pill you pick up at a pharmacy. It is an intensive medical procedure that can take several months to complete.

The Price Tag

  • Casgevy: Vertex Pharmaceuticals has set the list price at $2.2 million for the one-time treatment.
  • Lyfgenia: Bluebird Bio has set the wholesale acquisition cost at $3.1 million.

The Patient Journey

The administration of these therapies is physically demanding. Before the edited cells can be reinfused, the patient must undergo high-dose chemotherapy (typically utilizing busulfan). This chemotherapy is necessary to clear out the bone marrow to make room for the new, edited cells.

The chemotherapy process involves significant risks and side effects, including:

  • High risk of infection due to immune system suppression.
  • Mouth sores, nausea, and vomiting.
  • Infertility: The chemotherapy conditioning is toxic to reproductive organs. Patients generally need to bank eggs or sperm prior to treatment if they wish to have biological children in the future.

Implementation and Access

Vertex Pharmaceuticals is rolling out Casgevy slowly through a network of authorized treatment centers. As of early 2024, they are establishing roughly 50 to 75 authorized treatment centers across the United States. These centers must have extensive experience in stem cell transplantation.

A major focus now shifts to insurance coverage. Approximately 50% to 60% of people with sickle cell disease in the U.S. are covered by Medicaid. Because Medicaid is administered on a state-by-state basis, Vertex and Bluebird Bio must negotiate coverage terms individually with state agencies.

The Centers for Medicare & Medicaid Services (CMS) has announced a new “Cell and Gene Therapy Access Model.” This initiative aims to help states negotiate outcome-based agreements with manufacturers, potentially easing the financial burden on state budgets while ensuring patient access.

Frequently Asked Questions

Is Casgevy a permanent cure for sickle cell disease? While doctors are hesitant to use the word “cure” until decades of data exist, it is considered a “functional cure.” This means that while the patient still carries the genetic mutation, the symptoms of the disease are effectively eliminated. The edited cells are expected to persist for the patient’s lifetime.

Who is eligible for this treatment? The FDA approved Casgevy for patients aged 12 years and older who have recurrent vaso-occlusive crises. It is not currently approved for younger children or asymptomatic carriers (those with sickle cell trait).

Does the treatment change my DNA forever? Yes. CRISPR makes a permanent change to the DNA within your blood stem cells. When those stem cells divide, the new cells will also carry the edit. However, this edit is somatic, meaning it affects only your body and is not passed down to your children.

Why is chemotherapy required? The “edited” stem cells need space to grow. Your bone marrow is currently full of your original stem cells producing sickled cells. Chemotherapy (conditioning) wipes out the old marrow to allow the new, edited cells to “engraft” or take hold and start producing healthy blood.

Are there long-term risks with CRISPR? Because this is a new technology, researchers are monitoring for “off-target effects,” where the editing tool cuts DNA in the wrong place. In clinical trials for Casgevy, no significant off-target effects were observed. However, the FDA mandates a 15-year follow-up study for all patients receiving these gene therapies to monitor for long-term safety.